SVB Wealth LLC Grows Holdings in Amarin Co. plc (NASDAQ:AMRN)

SVB Wealth LLC boosted its position in Amarin Co. plc (NASDAQ:AMRN) by 100.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,000 shares of the biopharmaceutical company’s stock after buying an additional 30,000 shares during the quarter. SVB Wealth LLC’s holdings in Amarin were worth $52,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Axxcess Wealth Management LLC lifted its stake in shares of Amarin by 4.5% in the third quarter. Axxcess Wealth Management LLC now owns 1,274,283 shares of the biopharmaceutical company’s stock worth $1,172,000 after acquiring an additional 54,955 shares in the last quarter. LCM Capital Management Inc raised its position in shares of Amarin by 103.4% in the 3rd quarter. LCM Capital Management Inc now owns 704,159 shares of the biopharmaceutical company’s stock valued at $648,000 after purchasing an additional 358,000 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its stake in shares of Amarin by 35.7% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 649,152 shares of the biopharmaceutical company’s stock valued at $597,000 after buying an additional 170,670 shares during the last quarter. Hayek Kallen Investment Management grew its position in shares of Amarin by 83.6% during the third quarter. Hayek Kallen Investment Management now owns 622,643 shares of the biopharmaceutical company’s stock worth $573,000 after buying an additional 283,564 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. increased its stake in shares of Amarin by 18.9% in the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 129,200 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 20,500 shares during the last quarter. 22.25% of the stock is owned by hedge funds and other institutional investors.

Amarin Stock Up 2.0 %

NASDAQ:AMRN opened at $0.88 on Wednesday. Amarin Co. plc has a 52 week low of $0.65 and a 52 week high of $1.49. The company has a market cap of $362.74 million, a PE ratio of -6.31 and a beta of 1.98. The business’s 50 day moving average is $0.99 and its two-hundred day moving average is $0.93.

Amarin (NASDAQ:AMRN) last announced its quarterly earnings data on Thursday, February 29th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.04. The firm had revenue of $74.71 million for the quarter, compared to analysts’ expectations of $72.46 million. Amarin had a negative return on equity of 10.47% and a negative net margin of 19.26%. As a group, sell-side analysts expect that Amarin Co. plc will post -0.14 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Amarin in a research note on Friday, January 12th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $1.08.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.